emtricitabine

(redirected from Coviracil)
Also found in: Medical.
Related to Coviracil: rilpivirine, Tenofovir, elvitegravir

em·tri·cit·a·bine

 (ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)
n.
An antiviral drug, C8H10FN3O3S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]
Translations

emtricitabine

n emtricitabina
Mentioned in ?
References in periodicals archive ?
There are at least 10 antiretroviral drugs of the NRTI class that are currently under investigation in clinical trials, including FTC Coviracil, an improved form of the drug 3TC (Epivir)
Triangle's proprietary drug candidates under development for HIV and/or hepatitis B include Coviracil (emtricitabine), amdoxovir (formerly DAPD), and clevudine (formerly L-FMAU).
New reverse transcriptase inhibitors are in the works, with names like DAPD and Coviracil (FTC), both from Triangle Pharmaceuticals; calanolide A, from Sarawak MediChem; capravirine, from Agouron; DPC 083 and DPC 961, from DuPont; and TMC 125 and TMC 120, from Tibotec-Virco.
Triangle's proprietary drug candidates under development for human immunodeficiency virus and/or hepatitis include Coviracil (emtricitabine), Coactinon (emivirine), amdoxovir and clevudine.
Daniel Welch, Chairman and Chief Executive Officer of Triangle stated, "Triangle's strong progress toward commercialization continues with the acceptance by the Food and Drug Administration (FDA) of our New Drug Application (NDA) for Coviracil on November 1, 2002.
Triangle drug candidates under development for human immunodeficiency virus and/or hepatitis B virus include Coviracil (emtricitabine), Coactinon (emivirine), DAPD, L-FMAU and DMP-450.
Gilead's interest in Triangle is the co-formulation of Coviracil with Gilead's Viread into a single once-a-day pill that has the potential to become the gold standard for HIV therapy.
Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for marketing approval of Coviracil for the treatment of HIV disease has been accepted for filing.
Coviracil, an experimental nucleoside reverse-transcriptase inhibitor, was compared with d4T; and
Will Develop Co-Formulation of Viread(R) and Coviracil
The Company expects Coviracil to become its first product for which an NDA is submitted, marking a critical milestone in the Company's history.
today provided updated information on the development of two of its HIV compounds, Coviracil and Coactinon.